Monday, 10 August 2020


SARS-CoV-02: What are the chances of false negatives in tests?

25 April 2020 | News

Bio-Rad's ddPCR Asia Pacific Symposium is back for a 5th year, and this time Bio-Rad's going virtual

This May 2020, join BioRad's for a month of discovery with Droplet Digital PCR (ddPCR) – one of the most exciting technologies in biomedical science that has revolutionized nucleic acid detection and quantitation.

Pushing boundaries in research, biopharma and diagnostic testing, ddPCR is enabling scientists and clinicians to find answers that were previously unattainable.

Each week, we explore a key topic with leading experts in their fields.

Ready to discover ddPCR and how it can make a difference in your research? Join the conversation.

It starts with a Droplet. Ends in Discovery.

COVID-19 Detection


06 May 2020, Wednesday | 13:00 – 14:15 GMT+8

The current global outbreak of COVID-19 has seen millions infected and over 150,000 deaths worldwide.1 As the world grapples with shortages of tests and medical supplies, high false negative rates from current coronavirus tests is emerging as a new concern.


In Wuhan China, clinicians first observed that a number of highly symptomatic patients would repeatedly test negative for COVID 19, but could be confidently detected with ddPCR. Learn how ddPCR can be incorporated into the virology laboratory workflows for detection of SARS-CoV-22 to increase confidence and reduce false negative test results.

Introduction to Droplet Digital PCR


Richard Harrison
Digital Biology Marketing Manager, Asia Pacific, Bio-Rad Laboratories, Australia

 

ddPCR for Low Viral Load COVID 19 - the Wuhan Experience


Cyrus Zhao
Senior Product Manager, Greater China, Bio-Rad Laboratories, China

 

Rapid Deployment of a New COVID-19 ddPCR Assay in a Centralized CLIA Testing Laboratory in the United States


Dr Gary Pestano
Chief Development Officer, Biodesix, Inc, United States

 

Digital PCR Technology Enables Accurate and More Sensitive Solutions for COVID-19 Detection


Dr Qian Liang
Research & Development Lead, POCT diagnostics, Jiangsu Bioperfectus Technologies, China

 


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls